Myositis

What ‘CAR’ to drive? #CAR-T buzz was at #EULAR2025 In multiple #rheumatic #diseases #SLE #Scleroderma #Sjogrens #myositis Even #axial #SpA Who - active, not a lot of damage Which target 🎯 Which priming regiment What will results be compared to? Who will pay? @RheumNow

Janet Pope @Janetbirdope( View Tweet )

EULAR/ACR Classification Criteria for #ASyS, the new acronym of Antisynthetase Syndrome 🔺️Do not apply if patient is positive for other antibodies like SSA #EULAR2025 @RheumNow https://t.co/AD5tTipBtt

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
acr_session2.jpeg

EULAR 2025 – Day 3 Report

Jack Cush, MD

Highlights from today included presentations on imaging in vasculitis, a debate on whether to treat high risk pre-clinical RA, and EULAR Recommendations on a) Treatment of interstitial lung disease (ILD); b) Physical Activity in people with arthritis; and c) EULAR disease activity score for

Read Article
Puzzle pieces

Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD

Mrinalini Dey, MD

Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 continues to highlight the importance of CTD-ILD and the evolving landscape of therapeutic

Read Article
#EULAR2025 Abstr#OP0002 Promising new mode of action therapy for #myositis. Phase 2 RCT of efgartigimod (FcRn-i; coformulated with recombinant PH20) showed improvement in TIS & other key endpoints vs PBO at Wk24. Injection reaction common (23%). Will proceed to Phase 3 @RheumNow https://t.co/SuMolfcDkS

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Retrospective multicentre study of 122 anti-synthetase syndrome pts - 14 (11%) had cancer associated myositis (CAM). The CAM SIR= 5.4 (elevated vs gen. pop. p < 0.0001). These pts were older, often +Hx cancer, lower CK levels, less weakness, worse survival. CAM cluster= older https://t.co/nuKg3P89a8
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Vitamin D Headlines (5.9.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and lupus highlights from the past week on RheumNow.com. Triple positivity, the gut and CRPS, and hope for better outcomes with Vitamin D therapy. 

Read Article
International Myositis Assessment and Clinical Studies Group (IMACS) reached a consensus on ‘anti-synthetase syndrome’ as the preferred nomenclature and "ASyS" as the preferred abbreviation for the ‘anti-synthetase syndrome. https://t.co/TuTzVVZzZO https://t.co/qs5f1qATKi

Links:

Dr. John Cush @RheumNow( View Tweet )
Immune Checkpoint Inhib causing Myasthenia Gravis w/ poor outcomes - 16 ICI Rx pts (9 Lung CA, 7 other tumors) Dx w/ MG; 11 w/ overlap myositis. Mean onset @ 49d. All Rx wp steroids, 6 immunosuppressives, 5 plasma exchange; only 2 complete resp. 6 deaths re: MG complications https://t.co/re73lh2Xfs
Dr. John Cush @RheumNow( View Tweet )
Review of SARCOPENIA - a loss of muscle mass and function, with significant implications on physical performance. More common in RA, SSc, SpA, SLE, FM, myositis, and vasculitis https://t.co/tCXdoEn9xR https://t.co/Oi91niMn5M

Links:

Dr. John Cush @RheumNow( View Tweet )
Immune Checkpoint Inhib causing Myasthenia Gravis w/ poor outcomes - 16 ICI Rx pts (9 Lung CA, 7 other tumors) Dx w/ MG; 11 w/ overlap myositis. Mean onset @ 49d. All Rx wp steroids, 6 immunosuppressives, 5 plasma exchange; only 2 complete resp. 6 deaths re: MG complications https://t.co/PUc6kIE7FW
Dr. John Cush @RheumNow( View Tweet )
Review of SARCOPENIA - a loss of muscle mass and function, with significant implications on physical performance. More common in RA, SSc, SpA, SLE, FM, myositis, and vasculitis https://t.co/tCXdoEn9xR https://t.co/PvtmVCv2QJ

Links:

Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Cancer Survival with TNF Inhibitors (3.28.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

Read Article
An Unusual Consult for Myopathy Presentation by Dr. Kelsey Lemmen, at the Rheumatology Winter Clinical Symposia - Feb 2025 https://t.co/DYlzee6qcs https://t.co/nUxTC9roF9

Links:

Dr. John Cush @RheumNow( View Tweet )
FDA grants priority reviews to: - Nicalizumab (J&J; FcRn antibody) for use in Myasthenia gravis. - Upadacitinib (AbbVie; JAK inhib) for use in GCA - Namistat (BI: PDE4B inhib) for use in Idiopathic pulmonary fibrosis - Inalizumab (Hansen; anti-CD19) for use in IG4 rel Dz -… https://t.co/dsg9vZASrk https://t.co/8t2USASmm8
Dr. John Cush @RheumNow( View Tweet )
JAMA Case: A Woman With Painful Digital Ulcers - What would you order next? - chest CT w/ myositis-specific autoAb panel - dsDNA - SCL-70 & Centromere Abs - muscle biopsy https://t.co/t0WCIMtZg2 https://t.co/M1jBhnclLl

Links:

Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Opioid Deaths are Down (2.28.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.  Opioid deaths are down, IL-33 levels are up and Weight loss is in the news again this week!

Read Article
175px-Dermatitis2015.jpg

Misdiagnosis of Dermatomyositis

Jack Cush, MD

JAMA Dermatology reports a retrospective cohort study from Johns Hopkins reviewing mimic of dermatomyositis (DM), suggesting that DM and especially clinically amyopathic DM (CADM) are commonly and initially misdiagnosed as inflammatory skin disease (ISD).

The study was undertaken to

Read Article
JAMA Case: A Woman With Painful Digital Ulcers - What would you order next? - chest CT w/ myositis-specific autoAb panel - dsDNA - SCL-70 & Centromere Abs - muscle biopsy https://t.co/9T8mNDdJTs https://t.co/pTphzcuZKF

Links:

Dr. John Cush @RheumNow( View Tweet )
Risk Prediction Modeling in MDA5 Dermatomyositis Patients with Melanoma differentiation-associated gene 5 (MDA5) positive dermatomyositis (DM) are complicated and prone to interstitial lung disease, poor prognosis, and a high mortality. A new study suggests a risk prediction… https://t.co/v20ZCVZUQE https://t.co/GmWWQDpWUU
Dr. John Cush @RheumNow( View Tweet )
myositis, polymyositis, wikipedia

Risk Prediction Modeling in MDA5 Dermatomyositis

Jack Cush, MD

Patients with Melanoma differentiation-associated gene 5 (MDA5) positive dermatomyositis (DM) are complicated and prone to interstitial lung disease, poor prognosis, and a high

Read Article
RheumNow Podcast square

Valentine RNL 2025 Review (2.14.2025)

Jack Cush, MD

Dr. Jack Cush reviews highlights from RheumNow Live 2025 held in Dallas, TX on Feb. 8-9, 2025.

Read Article
Facing challenges in diagnosing idiopathic inflammatory myopathies? Check out our recent webinar to hear from Stanley J. Naides, MD, FACP, FACR, as he explores the role of autoantibody testing in autoimmune myositis diagnosis and phenotyping. Sponsored by LabCorp Rx. #Myositis… https://t.co/4jMevolO3k https://t.co/ObWPR8QFW2
Dr. John Cush @RheumNow( View Tweet )
Dazukibart Effective in Adults with Dermatomyositis Lancet reports that the use of dazukibart, a selective monoclonal antibody against interferon B (IFNβ), was clinically effective in reducing disease activity in adults with active dermatomyositis (DM).… https://t.co/7oRyxrFpar https://t.co/wA06Kzsdqg
Dr. John Cush @RheumNow( View Tweet )
QD Clinic - Treating Overlap with ILD Polyarthritis, ILD, Dermatomyositis - how to treat? Features Dr. Jack Cush. QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025 Register at https://t.co/2dcFVgu8z6 https://t.co/CsIpdS8hyd https://t.co/I92p5U3UTp

Links:

Dr. John Cush @RheumNow( View Tweet )

Recent Blogs

A Winning Season*

Jack Cush, MD
football.jpg

Winning is everything – in football and in medicine. Rheumatologists have achieved many successes but still struggle to win against a handful of rheumatic foes. This retrospective examines past wins and losses and helps us to look ahead to a new season.

Read Post
×